{"id": "370502", "url": "https://fevir.net/resources/Composition/370502", "date": "2025-10-21T10:47:22.217Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"], "versionId": "25", "lastUpdated": "2025-10-21T10:47:22.217Z"}, "type": {"text": "Participant Flow Report", "coding": [{"code": "ParticipantFlowReport", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowReport"}]}, "title": "Participant Flow Report for NCT03640312", "author": [{"display": "[No author listed.]"}], "status": "final", "contained": [{"id": "FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"]}, "name": "NCT03640312 Flow Group QUARTET LDQT", "type": "person", "quantity": 32, "membership": "enumerated", "description": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.", "resourceType": "Group", "characteristic": [{"code": {"text": "Research Study from which this is a flow group"}, "exclude": false, "valueReference": {"display": "NCT03640312"}}]}, {"id": "FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"]}, "name": "NCT03640312 Flow Group Candesartan", "type": "person", "quantity": 30, "membership": "enumerated", "description": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.", "resourceType": "Group", "characteristic": [{"code": {"text": "Research Study from which this is a flow group"}, "exclude": false, "valueReference": {"display": "NCT03640312"}}]}, {"id": "NCT03640312-flow-milestone-0-Overall-Study-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 32}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-0-Overall-Study-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "QUARTET LDQT", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-milestone-0-Overall-Study-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 30}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-0-Overall-Study-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Candesartan", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "STARTED at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-milestone-1-Overall-Study-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 32}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-1-Overall-Study-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "QUARTET LDQT", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "6 Week Follow Up at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-milestone-1-Overall-Study-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 28}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-1-Overall-Study-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Candesartan", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "6 Week Follow Up at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-milestone-2-Overall-Study-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 29}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-2-Overall-Study-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "QUARTET LDQT", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-milestone-2-Overall-Study-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 24}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-2-Overall-Study-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Candesartan", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "COMPLETED at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-milestone-3-Overall-Study-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 3}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-3-Overall-Study-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "QUARTET LDQT", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-milestone-3-Overall-Study-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"quantity": {"value": 6}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-milestone-3-Overall-Study-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Candesartan", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "NOT COMPLETED at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-reason-Overall-Study-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"category": {"text": "Lost to Follow-up"}, "quantity": {"value": 3}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-reason-Overall-Study-group-FG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "QUARTET LDQT", "reference": "#FG000"}, "variableRole": "population"}, {"observed": {"display": "Reasons for withdraw at Overall Study"}, "variableRole": "outcome"}]}, {"id": "NCT03640312-flow-reason-Overall-Study-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "title": "ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "status": "active", "statistic": [{"category": {"text": "Lost to Follow-up"}, "quantity": {"value": 6}, "statisticType": {"coding": [{"code": "STATO:0000047", "system": "https://fevir.net/sevco", "display": "Count"}]}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-flow-reason-Overall-Study-group-FG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ParticipantFlowEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "Candesartan", "reference": "#FG001"}, "variableRole": "population"}, {"observed": {"display": "Reasons for withdraw at Overall Study"}, "variableRole": "outcome"}]}], "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "relatesTo": [{"type": "cite-as", "targetMarkdown": "Participant Flow Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370502. Revised 2025-10-21. Available at: https://fevir.net/resources/Composition/370502. Computable resource at: https://fevir.net/resources/Composition/370502#json."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "370502", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-participant-flow-report", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"code": {"text": "FlowPreAssignmentDetails", "coding": [{"code": "participant-flow-details", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Participant Flow Details"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">NA - all enrolled participants were randomized.</div>", "status": "generated"}, "title": "Flow PreAssignment Details"}, {"code": {"text": "FlowRecruitmentDetails", "coding": [{"code": "participant-flow-details", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Participant Flow Details"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">120 were consented and assessed for eligibility. 58 were excluded for not meeting either inclusion or exclusion criteria, declining participation, or not showing up for randomization visits. Thus, these 58 individuals were not randomized, and 62 participants were randomized</div>", "status": "generated"}, "title": "Flow Recruitment Details"}, {"code": {"text": "FlowGroupList", "coding": [{"code": "groups", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Groups"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">QUARTET LDQT, Candesartan</div>", "status": "generated"}, "entry": [{"type": "Group", "display": "QUARTET LDQT", "reference": "#FG000"}, {"type": "Group", "display": "Candesartan", "reference": "#FG001"}], "title": "Flow Group List"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - STARTED at Overall Study", "reference": "#NCT03640312-flow-milestone-0-Overall-Study-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 Candesartan - STARTED at Overall Study", "reference": "#NCT03640312-flow-milestone-0-Overall-Study-group-FG001"}], "focus": {"display": "STARTED at Overall Study"}, "title": "STARTED at Overall Study"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - 6 Week Follow Up at Overall Study", "reference": "#NCT03640312-flow-milestone-1-Overall-Study-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 Candesartan - 6 Week Follow Up at Overall Study", "reference": "#NCT03640312-flow-milestone-1-Overall-Study-group-FG001"}], "focus": {"display": "6 Week Follow Up at Overall Study"}, "title": "6 Week Follow Up at Overall Study"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - COMPLETED at Overall Study", "reference": "#NCT03640312-flow-milestone-2-Overall-Study-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 Candesartan - COMPLETED at Overall Study", "reference": "#NCT03640312-flow-milestone-2-Overall-Study-group-FG001"}], "focus": {"display": "COMPLETED at Overall Study"}, "title": "COMPLETED at Overall Study"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - NOT COMPLETED at Overall Study", "reference": "#NCT03640312-flow-milestone-3-Overall-Study-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 Candesartan - NOT COMPLETED at Overall Study", "reference": "#NCT03640312-flow-milestone-3-Overall-Study-group-FG001"}], "focus": {"display": "NOT COMPLETED at Overall Study"}, "title": "NOT COMPLETED at Overall Study"}, {"code": {"text": "Participant Flow Results", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 QUARTET LDQT - Reasons for withdraw at Overall Study", "reference": "#NCT03640312-flow-reason-Overall-Study-group-FG000"}, {"type": "Evidence", "display": "ParticipantFlowEvidence: NCT03640312 Candesartan - Reasons for withdraw at Overall Study", "reference": "#NCT03640312-flow-reason-Overall-Study-group-FG001"}], "focus": {"display": "Reasons for withdraw at Overall Study"}, "title": "Reasons for withdraw at Overall Study"}]}